Introduction
============

Supplemental long-term oxygen therapy (LTOT) improves the survival, exercise capacity, and quality of life in patients with chronic obstructive pulmonary disease (COPD) and hypoxemia ([@B1]) as well as in those with sequelae of tuberculosis ([@B2]). LTOT has also been reported to improve the quality of life in patients with chronic interstitial lung disease (ILD) ([@B3]). The number of patients receiving LTOT has increased in Japan ([@B4]) and is likely to continue to increase because of the aging population.

According to the Global Initiative for Chronic Obstructive Lung Disease guideline, LTOT is indicated in patients who have a PaO~2~ ≤55 Torr or an SaO~2~ ≤88% with or without hypercapnia and in those with a PaO~2~ of 55-60 Torr or an SaO~2~ of 88% if there is evidence of pulmonary hypertension suggesting congestive heart failure ([@B1]).

After oxygen therapy is started, blood gases should be checked to ensure that oxygenation is satisfactory without retention of CO~2~ and/or worsening acidosis. An American Thoracic Society/European Respiratory Society position paper reported that an arterial blood gas (ABG) analysis was the preferred method for determining the need for oxygen, as it includes acid-base information ([@B5]). Patients with chronic respiratory failure who need LTOT are at risk of CO~2~ retention as a result of the administration of excessive oxygen; therefore, it is important to monitor the blood CO~2~ level regularly. However, the evaluation of the blood CO~2~ level every time a patient visits the outpatient department is difficult because blood gas sampling is invasive and painful.

End-tidal CO~2~ (EtCO~2~), which is measured using a capnometer, is positively correlated with blood CO~2~ ([@B6]) and is now part of the standard of care for all mechanically ventilated patients receiving general anesthesia and routine monitoring in intensive-care settings ([@B7]). In July 2018, the CapnoEye™ MC600 (Nissei, Osaka, Japan), a novel capnometer that measures the EtCO~2~ level correctly in patients who are breathing spontaneously ([Fig. 1](#g001){ref-type="fig"}), was approved for use in Japan, but its clinical value in patients receiving LTOT remains unclear.

![The CapnoEye^TM^ capnometer. The CapnoEye^TM^ can measure EtCO~2~ six times during spontaneous breathing. The EtCO~2~ is measured while holding the EtCO~2~ sensor with the hand opposite to the one with the SpO~2~ sensor attached and placing the mouthpiece in the mouth. EtCO~2~, end-tidal carbon dioxide.](1349-7235-59-1711-g001){#g001}

The blood CO~2~ levels need to be measured noninvasively in outpatients with chronic respiratory failure because of the difficulties inherent in routine measurement of blood arterial CO~2~. The aim of this study was to evaluate the ability of the CapnoEye™ MC600 to measure EtCO~2~ and to assess the relationship between EtCO~2~ and the PCO~2~ level in patients receiving LTOT.

Materials and Methods
=====================

The study protocol was approved on June 1, 2018, by our institutional review board (approval number 680). The requirement for written informed consent was waived due to the use of an opt-out method ([@B8]). The study population consisted of 61 consecutive outpatients with chronic respiratory failure who received LTOT and underwent blood sampling between July 2017 and March 2018.

EtCO~2~ measurements
--------------------

The mainstream EtCO~2~ level was measured using the CapnoEye™. Patients performed a tidal volume (TV) maneuver with the mouthpiece at a constant flow rate and in a relaxed position six times while holding the EtCO~2~ sensor with the hand opposite to the one with the SpO~2~ sensor attached. The EtCO~2~ was analyzed automatically as the average of the readings obtained during the six TV maneuvers and displayed on the monitor. The measurements were supported by experienced technicians in all cases.

Data collection
---------------

The flow of the enrolled patients throughout the study is shown in [Fig. 2](#g002){ref-type="fig"}. Between July 2017 and March 2018, 89 patients who visited our outpatient department and received LTOT were considered for enrollment. Twenty-eight patients were excluded because a lack of either EtCO~2~ or partial pressure of venous carbon dioxide (PvCO~2~) data, thus leaving 61 patients for inclusion in the study. The correlations between EtCO~2~, PvCO~2~, and pulmonary function tests were analyzed in these 61 patients (Method 1). Forty of these patients were excluded because they were not admitted for an observation period, thereby leaving 21 patients who had been admitted for additional analysis. The baseline data for these 21 patients were collected when they were in a stable condition, i.e., with stable vital signs, a normal level of consciousness, and an assessment of at least one month before the most recent admission. The EtCO~2~ data at baseline were compared with those obtained during the admission period and correlations between ΔEtCO~2~, ΔPvCO~2~, and pulmonary function tests were sought (Method 2).

![Consort flow diagram. Of the 89 patients screened, 28 were excluded because neither the EtCO~2~ or PvCO~2~ measurements were recorded, thus leaving 61 patients for enrolment in the study (Method 1). Next, a further 40 patients were excluded because they were not admitted during the observation period, thereby leaving 21 patients who had been admitted for further analysis (Method 2).](1349-7235-59-1711-g002){#g002}

Pulmonary function tests were performed using a rolling seal-type spirometer (Fudac-77; Fukuda Denshi, Tokyo, Japan). The medical records of each patient were also reviewed.

Statistical analyses
--------------------

Correlations were analyzed using the Spearman's rank correlation coefficient. The change in the EtCO~2~ level according to the respiratory status in the same patients was analyzed using Wilcoxon's signed rank test. A multiple regression analysis was used to predict the values of dependent and independent variables. Logistic regression and receiver-operating characteristic curve analyses were used to evaluate the diagnostic performance of EtCO~2~. The descriptive data are shown as the median, frequency, and percentage. All reported p-values are two-sided. The data were analyzed using the JMP 9 software program, version 9.0.3 (SAS Institute, Cary, USA). A p value ＜0.05 was considered statistically significant.

Results
=======

The characteristics of the 61 patients \[36 men, 25 women; median age 74 (34-96) years old\] who received LTOT at our hospital during the study period are shown in [Tables 1](#t001){ref-type="table"} and [2](#t002){ref-type="table"}. All patients had a Glasgow Coma Scale score ＞13, indicating a clear consciousness level. None of the patients were ventilated via tracheostomy. Eight patients required noninvasive positive pressure ventilation for COPD, ILD, or sequelae of tuberculosis. Fifty-four patients required oxygen therapy for 24 hours, and 7 required it only when sleeping or on exertion.

###### 

Demographic and Clinical Characteristics of the 61 Patients in the Study at Baseline.

                                All (n=61)         Male (n=36)        Female (n=25)      p value
  ----------------------------- ------------------ ------------------ ------------------ ----------
  Age, years                    74 (34-96)         75.5 (54-90)       72 (34-96)         0.7579
  Smoking history, pack years   7 (0-160)          50 (0-160)         0 (0-88.5)         \<0.0001
  Body mass index               19 (12-39)         20.5 (14-32.6)     17.6 (12-39)       0.1164
  EtCO~2~, mmHg                 31 (18-41)         34.5 (18-48)       37 (25-53)         0.2013
  PvCO~2~, mmHg                 49 (25-75)         50 (25-75)         48 (33-72)         1
  PvCO~2~- EtCO~2~              15 (-1.4, 34)      15 (-1.4, 34)      14.5 (8.5-26)      0.3589
  FEV~1~, L                     1.32 (0.43-3.01)   1.15 (0.43-3.01)   1.4 (0.55-1.99)    0.2674
  %FEV~1~, %                    54 (25-132)        53.9 (25-131)      66.5 (34.9-132)    0.1964
  FVC, L                        2.14 (0.6-4.7)     2.58 (0.6-4.7)     1.56 (0.79-2.96)   0.0057
  %FVC, %                       77 (31-134)        79 (31.2-134)      64.5 (39-129)      0.2184
  FEV~1~%, %                    66.1 (23-97)       62 (23-88)         73.1 (61-97)       0.0084
  TV, L                         0.66 (0.21-1.4)    0.72 (0.21-1.4)    0.48 (0.37-1.17)   0.176
  Oxygen flow rate at rest      2 (0-5)            2 (0-5)            2 (0-4)            0.8577
  NPPV, n (%)                   8                  6                  2                  0.6363
  IPAP, cmH~2~O                 9 (0-12)           8 (0-12)           11 (8-11)          0.4478
  EPAP, cmH~2~O                 4 (4-8)            4 (4-8)            4                  0.3291
  Admission, n (%)              21                 14                 7                  0.3606
  ∆EtCO~2~, mmHg)               4 (-8, 16)         0 (-8, 16)         7.5 (-3, 13)       0.0543
  ∆PvCO~2~, mmHg)               5 (-5, 21)         4 (-5, 21)         7 (-1.7, 12)       0.6926
  Underlying diseases, n (%)                                                             
  COPD                          31 (50.8)          23 (37.7)          8 (13.1)           0.0143
  ILD                           17 (27.9)          8 (13.1)           9 (14.8)           0.2379
  TBsq                          6 (9.8)            5 (8.2)            1 (1.6)            0.2021
  Other disease                 7 (11.5)           0                  7 (11.5)           0.0007

The data are presented as the median (range) or number (percentage). COPD: chronic obstructive pulmonary disease, EPAP: expiratory positive airway pressure, EtCO~2~: end-tidal carbon dioxide, FEV~1~: forced expiratory volume in one second, FVC: forced vital capacity, ILD: interstitial lung disease, IPAP: inspiratory positive airway pressure, NPPV: noninvasive positive pressure ventilation, PvCO~2~: partial pressure of venous carbon dioxide, TBsq: sequelae of tuberculosis, TV: tidal volume

###### 

Baseline Characteristics of Patients with COPD, ILD and Other Diseases.

                                COPD (n=31)        ILD (n=17)         Other diseases (n=13)   p value
  ----------------------------- ------------------ ------------------ ----------------------- ----------
  Age, years                    75 (41-96)         72 (54-87)         74 (34-90)              0.4985
  Sex, n (%)                                                                                  
  Male                          23                 8                  5                       0.0444
  Female                        8                  9                  8                       
  Smoking history, pack years   50 (0-150)         0 (0-160)          0                       \<0.0001
  Body mass index               21 (14-28.2)       18.9 (12-39)       16.2 (14.1-19.5)        0.0079
  EtCO~2~, mmHg                 34 (18-46)         36 (27-50)         42 (30-53)              0.0083
  PvCO~2~, mmHg                 47 (25-75)         46 (37-72)         62 (44-73)              0.0064
  PvCO~2~- EtCO~2~              13 (-1.4, 34)      8.5 (8-28)         19.5 (14-26)            0.075
  FEV~1~, L                     1.14 (0.43-2.84)   1.81 (0.65-3.01)   0.77 (0.43-1.99)        0.0128
  %FEV~1~, %                    54 (25-132)        100 (34.9-131)     46.9 (37.7-73)          0.0026
  FVC, L                        2.6 (0.82-4.7)     2.08 (0.98-3.39)   0.93 (0.6-3.06)         0.0015
  %FVC, %                       80.4 (40-134)      85.4 (41-111)      41.2 (31.2-65)          0.0006
  FEV~1~%, %                    60.5 (23-84)       78.5 (64.3-97)     74.7 (53.2-88.9)        \<0.0001
  TV, L                         0.72 (0.37-1.4)    0.81 (0.28-1.18)   0.45 (0.21-0.81)        0.0052
  Oxygen flow rate at rest      2 (0-5)            2 (0-4)            2 (1-4)                 0.8734
  NPPV, n (%)                   3                  1                  4                       0.013
  IPAP                          10 (0-12)          0                  9.5 (8-11)              0.2336
  EPAP                          4 (4-8)            7                  4                       0.2401
  Admission, n (%)              10                 3                  8                       0.1815
  ∆EtCO~2~, mmHg                1 (-8, -14)        -4 (-6, -4)        7.5 (-2, -16)           0.0755
  ∆PvCO~2~, mmHg                6 (0-12)           -1.7 (-5, -3)      7 (-1, -21)             0.0716

The data are presented as the median (range) or number (percentage). COPD: chronic obstructive pulmonary disease, EPAP: expiratory positive airway pressure, EtCO~2~: end-tidal carbon dioxide, FEV~1~: forced expiratory volume in one second, FVC: forced vital capacity, ILD: interstitial lung disease, IPAP: inspiratory positive airway pressure, NPPV: noninvasive positive pressure ventilation, PvCO~2~: partial pressure of venous carbon dioxide, TV: tidal volume

The underlying diseases were COPD in 31 patients, ILD in 17, sequelae of tuberculosis in 6, and other lung disease in 7. No patient had chronic kidney disease. The median EtCO~2~ was 31 (18-41) mmHg and the median PvCO~2~ was 49 (25-75) mmHg. On pulmonary function testing, the patients had a median FEV~1~ of 1.32 (0.43-3.01) L, a %FEV~1~ of 54% (25-132%), an FVC of 2.14 (0.6-4.7) L, and a %FVC of 77% (31-134%). The patient characteristics are shown according to sex in [Table 1](#t001){ref-type="table"}. There were significant differences in the smoking history, FVC, FEV~1~%, and underlying diseases between the study groups.

There were significant correlations between EtCO~2~ and PvCO~2~ (r=0.63), FEV~1~ (r=-0.44), %FEV~1~ (r=-0.36), FVC (r=-0.54), and %FVC (r=-0.64) and between %FEV~1~ and %FVC (r=0.52; [Fig. 3](#g003){ref-type="fig"}). A multivariate linear regression analysis was performed to determine if PvCO~2~ could be predicted on the basis of EtCO~2~, %FEV~1~, and %FVC. The findings were statistically significant for EtCO~2~ \[regression coefficient beta, 0.63; 95% confidence interval (CI) 0.58-1.48, p＜0.001\] and %FEV~1~ (regression coefficient beta, -0.3; 95% CI -0.22\--0.02, p=0.0189) but not for %FVC (regression coefficient beta, -0.11; 95% CI -0.07-0.16, p=0.458). There was a significant correlation between EtCO~2~ and PvCO~2~ in patients with COPD (r=0.5) and in those with ILD (r=0.63; [Fig. 4](#g004){ref-type="fig"}).

![Correlations of EtCO~2~ with pulmonary function test results. EtCO~2~ was measured in outpatients with chronic respiratory failure who were receiving long-term oxygen therapy. (A) There was a significant positive correlation of EtCO~2~ with PvCO~2~ (r=0.63) and (B) a significant negative correlation of EtCO~2~ with FEV~1~ (r=-0.44), (C) %FEV~1~ (r=-0.36), (D) FVC (r=-0.54), and (E) %FVC (r=-0.64). (F) There was a significant positive correlation of %FEV~1~ with %FVC (r=0.52). COPD: chronic obstructive pulmonary disease, EtCO~2~: end-tidal carbon dioxide, FEV~1~: forced expiratory volume in one second, FVC: forced vital capacity, ILD: interstitial lung disease, PvCO~2~: partial pressure of venous carbon dioxide](1349-7235-59-1711-g003){#g003}

![Correlations of EtCO~2~ with PvCO~2~ in outpatients with COPD or ILD. There was a significant positive correlation of EtCO~2~ with PvCO~2~ in (A) outpatients with COPD (r=0.5) and (B) with ILD (r=0.63). COPD: chronic obstructive pulmonary disease, EtCO~2~: end-tidal carbon dioxide, ILD: interstitial lung disease, PvCO~2~: partial pressure of venous carbon dioxide](1349-7235-59-1711-g004){#g004}

There were significant correlations between the PvCO~2~ and EtCO~2~ gradient and the body mass index (BMI; r=-0.35) and %FEV~1~ (r=-0.33); however, there was no significant correlation with the TV (r=-0.14) or %FVC (r=-0.08; [Fig. 5](#g005){ref-type="fig"}). A multivariate linear regression analysis was performed to predict the PvCO~2~ and EtCO~2~ gradient based on the BMI and %FEV~1~. The results were statistically significant for the BMI (regression coefficient beta, -0.34; 95% CI -1.16, -0.09, p=0.0235) but not for %FEV~1~ (regression coefficient beta, -0.021; 95% CI -0.15, 0.02, p=0.1476).

![Correlations of the PvCO~2~ and EtCO~2~ gradient with the BMI and pulmonary function test results. (A) There was a significant negative correlation of the PvCO~2~ and EtCO~2~ gradient with the BMI (r=-0.35) and (B) %FEV~1~ (r=-0.33) and (C) no significant correlation of the PvCO~2~ and EtCO~2~ gradient with the TV (r=-0.14) or (D) %FVC (r=-0.08). EtCO~2~: end-tidal carbon dioxide, FEV~1~: forced expiratory volume in one second, FVC: forced vital capacity, PvCO~2~: partial pressure of venous carbon dioxide, TV: tidal volume](1349-7235-59-1711-g005){#g005}

The median time interval between the first visit and the day of admission was 2 (1-24) months. The EtCO~2~ levels on the day of admission were significantly higher than those in the same patients when they were in a stable condition (p=0.0049; [Fig. 6](#g006){ref-type="fig"}). Furthermore, there were significant correlations between ΔEtCO~2~ and ΔPvCO~2~ (r=0.4), TV (r=0.43), %FEV~1~ (r=-0.4), and %FVC (r=-0.45; [Fig. 7](#g007){ref-type="fig"}) in the study population overall. However, there was no statistically significant difference between the EtCO~2~ level on the day of admission and that in a stable condition in the COPD and ILD groups.

![A comparison of EtCO~2~ between patients who were admitted to the hospital according to their respiratory status. The EtCO~2~ was significantly higher in patients with respiratory failure who were admitted immediately after measurement of EtCO~2~ than in the same patients when they were in a stable condition (p=0.0049). EtCO~2~: end-tidal carbon dioxide](1349-7235-59-1711-g006){#g006}

![Correlations of ΔEtCO~2~ with ΔPvCO~2~ and pulmonary function test results. (A) There was a significant positive correlation of ΔEtCO~2~ with ΔPvCO~2~ (r=-0.4) and a significant negative correlation of ΔEtCO~2~ with the (B) TV (r=-0.43), (C) %FEV~1~ (r=-0.4), and (D) %FVC (r=-0.45). EtCO~2~: end-tidal carbon dioxide, FEV~1~: forced expiratory volume in one second, FVC: forced vital capacity, PvCO~2~: partial pressure of venous carbon dioxide, TV: tidal volume](1349-7235-59-1711-g007){#g007}

The receiver-operating characteristic curve for EtCO~2~ predicting hypercapnia as PvCO~2~＞45 mmHg is shown in [Fig. 8A](#g008){ref-type="fig"}. The area under the curve was 0.849 for EtCO~2~. The optimum EtCO~2~ cut-off point for identifying hypercapnia was 34 mmHg (sensitivity 79.1%, specificity 88.9%). The receiver-operating characteristic curve for EtCO~2~ predicting hypercapnia as PvCO~2~ ＞70 mmHg is shown in [Fig. 8B](#g008){ref-type="fig"}. The area under the curve was 0.806, and the optimum cut-off point was 38 mmHg for EtCO~2~ (sensitivity 100%, specificity 69.1%).

![Ability of the receiver-operating characteristic curve of EtCO~2~ to predict hypercapnia. (A) A plot of the EtCO~2~ curve for the prediction of hypercapnia defined as PvCO~2~ \>45 mmHg with an area under the curve of 0.849. (B) A plot of the EtCO~2~ curve for the prediction of hypercapnia defined as a PvCO~2~ of \>70 mmHg with an area under the curve of 0.806.](1349-7235-59-1711-g008){#g008}

Discussion
==========

This is the first report on the value of EtCO~2~ as measured by the CapnoEye™ in patients with chronic respiratory failure receiving LTOT. There was a significant correlation of EtCO~2~ with PvCO~2~ and an association of the PvCO~2~ and EtCO~2~ gradient with BMI. The EtCO~2~ cut-off level of 34 mmHg was useful for predicting CO~2~ retention and deterioration of respiratory status in the outpatient department.

EtCO~2~ measurements obtained by a capnometer have been widely accepted as a sensitive method for reflecting the PaCO~2~ level in intubated and mechanically ventilated patients. However, few studies have investigated the usefulness of EtCO~2~ in patients who are breathing spontaneously ([@B9]-[@B11]). One of the reported advantages of capnometry is its ability to obtain a reliable estimate of EtCO~2~ during a vital capacity maneuver in patients with chronic respiratory disease who are breathing spontaneously ([@B9]). In the present study, the EtCO~2~ value was measured using the CapnoEye™ during a TV maneuver and compared with that obtained during a vital capacity maneuver; the TV maneuver is easy for patients with respiratory failure to perform because it needs only spontaneous breathing.

It is well known that PaCO~2~ is the gold standard for the evaluation of hypercapnia; however, PvCO~2~ has also been reported to have good concordance with PaCO~2~ and to be a reliable, feasible, and safe alternative to repeated ABG analyses in patients with severe hypoxemic and/or hypercapnic respiratory failure ([@B12]). Therefore, PvCO~2~ was thought to be a useful surrogate marker of PaCO~2~ for the evaluation of hypercapnia in the present study.

The correlation of EtCO~2~ and PaCO~2~ has been reported to be unreliable in some clinical situations, and no correlation was found between EtCO~2~ and PaCO~2~ when the physiologic dead space was substantially elevated ([@B13]-[@B19]). Physiologic dead space ventilation is the sum of the anatomic dead space from the conducting airways and the alveolar dead space arising from a disease process and/or therapy.

The EtCO~2~ level is normally 5 mmHg lower than that of PaCO~2~ because of the mixing of CO~2~ containing alveolar gas and gas devoid of CO~2~ from the anatomic dead space ([@B20]). In patients with lung disease, the additional alveolar dead space further dilutes the EtCO~2~ relative to the PaCO~2~ ([@B20]). For example, the normal ratio of the physiologic dead space to TV (VD/VT) is 0.2-0.35 ([@B21]) but has been found to be 0.4-0.55 in patients with acute lung injury as a result of the additional alveolar dead space ([@B22]).

In the present study, the BMI was the only factor found to have a negative effect on the PvCO~2~ and EtCO~2~ gradient in a multivariate analysis, with no significant effect of TV. These findings are similar to those of Ickx et al., who found that the PaCO~2~ and EtCO~2~ gradient was negatively correlated with weight in small children and attributed this finding to the high ratio of dead space to TV (V~D~/V~T~) ([@B23]). Therefore, in the present study, the PvCO~2~ and EtCO~2~ gradient may have been correlated with dead space.

In general, in patients with COPD, progressive airflow limitations and emphysematous destruction were considered to increase the alveolar dead space, which might have caused the inequality in the ventilation/perfusion (V/Q) ratio. However, Sandek et al. found no significant correlation between the air flow obstruction measured by spirometry and the V/Q ratio ([@B24]). In the present study, %FEV~1~ was not a significant independent predictor of the PvCO~2~ and EtCO~2~ gradient. This finding is consistent with a previous speculation that inequality in the V/Q ratio might be buffered by underlying pathophysiological processes, including hypoxic vasoconstriction and active collateral ventilation ([@B24], [@B25]).

The positive mechanical pressure used when measuring EtCO~2~ in intubated and mechanically ventilated patients might increase the ventilation of the atelectatic lobe and reduce intravascular pulmonary fluid iatrogenically, leading to a V/Q mismatch and additional alveolar dead space ([@B26]). The mechanical dead space added by the endotracheal tube might further increase the PvCO~2~ and EtCO~2~ gradient. In our study, the exclusion of mechanically ventilated patients resulted in a reduction in dead space ventilation and might explain the strong correlation found between PvCO~2~ and EtCO~2~ even in patients with chronic respiratory failure.

EtCO~2~ was correlated with both FEV~1~ and FVC in this study. There has been a similar report of a significant correlation of FEV~1~ with EtCO~2~ measured using a capnometer ([@B11], [@B12]); however, to our knowledge, this is the first report of a correlation between EtCO~2~ and FVC. Although the mechanism underlying the elevation of EtCO~2~ in response to decreases in FEV~1~ remains unclear, a reduced FEV~1~ value is associated with the severity of obstructive lung disease, and obstruction of the terminal bronchi has been cited as a reason for hypoventilation of the alveoli and a cause of CO~2~ retention ([@B27], [@B28]). In the present study, FVC was strongly correlated with FEV~1~, so FEV~1~ may be a confounding factor that influenced the correlation between EtCO~2~ and FVC.

EtCO~2~ has previously been reported to be correlated with PCO~2~ in patients with COPD ([@B9]); however, there has been no study of the correlation between EtCO~2~ and PCO~2~ in patients with ILD. In this study, EtCO~2~ was confirmed to be correlated with PvCO~2~ not only in patients with COPD but also in those with ILD. This finding highlights the value of EtCO~2~ for predicting hypercapnia in both obstructive and restrictive lung disease.

EtCO~2~ on the day of admission was significantly higher than that recorded when the patients were in a stable condition. The ΔEtCO~2~ was correlated with the ΔPvCO~2~, suggesting that elevation of EtCO~2~ may be a sign of an increasing PvCO~2~ level over time. The patients in our study were in an unstable respiratory condition when they were admitted and unable to undergo respiratory function testing. However, EtCO~2~ was measured successfully in these patients using the CapnoEye™ because the protocol required for the TV maneuver is much easier to perform than that for the VC maneuver, regardless of the respiratory status. Furthermore, the FEV~1~, FVC, and TV values measured when the patients were in a stable condition were negatively correlated with the ΔEtCO~2~ and ΔPvCO~2~. Therefore, we assume that the elevation of the CO~2~ level was easier to observe in patients with an impaired lung function than in those with a preserved lung function. The regular measurement of EtCO~2~ on an outpatient basis using the CapnoEye™ may help detect deterioration of the respiratory status and the need for hospital admission in patients with respiratory failure.

It is well known that CO~2~ retention depresses awareness, even to the point of total loss of consciousness, so monitoring the blood CO~2~ level is an important component of the patient assessment. Previous studies that used PvCO~2~ to screen for potential hypercapnia found that it had a sensitivity of 79% when a cut-off point of ＞45 mmHg was used ([@B29]). Therefore, the screening cut-off in the present study was defined as a PvCO~2~ of ＞45 mmHg, and the optimum cut-off point for hypercapnia was set at an EtCO~2~ of ＞34 mmHg. Furthermore, the elevation of PaCO~2~ to ＞70-75 mmHg has been reported to reduce the level of awareness ([@B30]). An EtCO~2~ of ＞38 mmHg was shown to be a possible biomarker of a PvCO~2~＞70 mmHg. By determining the cut-off point for EtCO~2~, the evaluation of the increase in EtCO~2~ over time may be able to predict the exacerbation of respiratory failure, thereby allowing for the early treatment and avoidance of admission.

Several limitations associated with the present study warrant mention, including its retrospective design, single-institution setting, small sample size, and inclusion of patients who needed differing oxygen flow rates. Furthermore, PvCO~2~ was measured instead of PaCO~2~, and the difference between the venous and arterial CO~2~ levels may be influenced by the cardiac output and tissue consumption; therefore, our ability to evaluate the correlation between EtCO~2~ and PaCO~2~ accurately was limited. Other limitations that restricted our ability to evaluate the usefulness of EtCO~2~ in patients with a deteriorating respiratory status included the lack of clinical data besides EtCO~2~ and PvCO~2~ in patients who required hospital admission. Finally, the CapnoEye™ can only evaluate EtCO~2~ in patients who are alert and breathing spontaneously and is thus unsuitable for use with patients who are unconscious.

Conclusion
==========

This is the first study to demonstrate the correlation of EtCO~2~ and PvCO~2~ with the pulmonary function in spontaneously breathing patients with chronic respiratory failure. Repeated EtCO~2~ measurements were obtained noninvasively by the CapnoEye™. The CapnoEye™ was convenient and useful for estimating PvCO~2~. The BMI was identified as a possible predictor of the PvCO~2~ and EtCO~2~ gradient. An increase in EtCO~2~ to ＞34 mmHg may indicate the deterioration of the respiratory status in patients with chronic respiratory failure receiving LTOT.
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